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Abstract 
Background: The primary aim of this study was to assess the outcome of elderly intensive care unit (ICU) patients 
treated during the spring and autumn COVID-19 surges in Europe.
Methods: This was a prospective European observational study (the COVIP study) in ICU patients aged 70 years 
and older admitted with COVID-19 disease from March to December 2020 to 159 ICUs in 14 European countries. An 
electronic database was used to register a number of parameters including: SOFA score, Clinical Frailty Scale, co-mor-
bidities, usual ICU procedures and survival at 90 days. The study was registered at ClinicalTrials.gov (NCT04321265).
Results: In total, 2625 patients were included, 1327 from the first and 1298 from the second surge. Median age was 
74 and 75 years in surge 1 and 2, respectively. SOFA score was higher in the first surge (median 6 versus 5, p < 0.0001). 
The  PaO2/FiO2 ratio at admission was higher during surge 1, and more patients received invasive mechanical ventila-
tion (78% versus 68%, p < 0.0001). During the first 15 days of treatment, survival was similar during the first and the 
second surge. Survival was lower in the second surge after day 15 and differed after 30 days (57% vs 50%) as well as 
after 90 days (51% vs 40%).
Conclusion: An unexpected, but significant, decrease in 30-day and 90-day survival was observed during the second 
surge in our cohort of elderly ICU patients. The reason for this is unclear. Our main concern is whether the widespread 
changes in practice and treatment of COVID-19 between the two surges have contributed to this increased mortal-
ity in elderly patients. Further studies are urgently warranted to provide more evidence for current practice in elderly 
patients.
Trial registration number: NCT04 321265, registered March 19th, 2020.
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Introduction
The first surge of the COVID-19 pandemic between 
March and May 2020 affected the elderly population dis-
proportionally. Elderly patients were over-represented 
both among ICU admissions and among non-survi-
vors [1]. The hospital mortality in all ICU patients was 
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observed to be around 40–50%, but a higher mortality 
was seen in the elderly and frail population [2, 3].
Thus, a robust prognostic stratification of elderly 
patients, many of whom had multiple co-morbidities, 
posed significant challenges in a disease which had not 
previously been encountered. In addition to established 
and new disease severity scores, geriatric characteristics 
notably frailty, co-morbidity and functional status were 
soon confirmed to be important prognostic factors in 
elderly COVID-19 patients [3–6]. Clinical studies were 
quickly launched focusing on potential novel treatments 
and the management of patients with COVID-19. These 
included respiratory management, such as the role of 
mechanical ventilation and prone positioning as well as 
pharmacological treatment (e.g. corticosteroids, antico-
agulation and anti-inflammatory agents) [7, 8].
During the summer months of 2020, the spread of 
the virus declined. However, it became evident by early 
autumn that a second surge of the SARS-Cov-2 pandemic 
was imminent [9]. In contrast to the first surge, health 
care systems had now acquired an increased understand-
ing of this disease. The pathophysiology of COVID-19 
disease was described, and it was possible to predict the 
epidemiology of the disease based on modelling from 
the previous surge. Furthermore, at least theoretically, 
“test, track and isolate” was in operation and more robust 
measures such as “shielding” vulnerable individuals such 
as the elderly and frail were in place [10].
The aim of this study was to assess a possible outcome 
difference in the first and the second surge of the pan-
demic in critically ill elderly ICU patients. The hypothesis 
was that outcome of elderly ICU patients with COVID-
19 improved during the second surge of the pandemic 
due to implemented changes in practice, based on expe-
rience and evidence available.
Methods
Design and setting
The study was a prospective observational multi-centre 
study of COVID-19 patients aged 70  years and older 
admitted to 159 ICUs in 14 European countries, called 
the COVIP study. Recruitment took place from 19 March 
to 31 December 2020. A list of collaborators is shown in 
Additional file 1. A map of participating ICUs is shown 
in Additional file  2. Recruitment in countries over the 
two different time periods is shown in Additional file 3. 
Recruitment within the individual countries in relation 
to the start of the study is shown in Additional file  4. 
The study was organised by the Very old Intensive care 
Patients (VIP) project [11, 12] within the European 
Society of Intensive Care Medicine (ESICM) which also 
endorsed the study (www. vipst udy. org). National coor-
dinators were responsible for the recruitment of ICUs 
and for obtaining national and local ethical permission. 
In addition, national coordinators supervised patient 
recruitment. Due to variations in requirement for ethical 
consent, some countries could recruit patients without 
upfront informed consent, while others had to obtain it. 
The study deliberately allowed for co-enrolment of study 
patients to other COVID-19 studies. The study was reg-
istered on ClinicalTrials.gov (ID: NCT04321265) and 
adhered to the European Union General Data Privacy 
Regulation (GDPR) directive.
Study preparation started during the first phase of the 
pandemic, and recruitment commenced on 19 March 
2020. Throughout the pandemic, recruitment to the 
COVIP study was monitored by weekly virtual steering 
group meetings. The first recruitment period, represent-
ing the first surge of the pandemic, was defined as from 
19 March until 26 May 2020, and the second recruitment 
period, reflecting the second surge, from 1 September to 
31 December 2020. This was also reflected by the num-
ber of ICU patients published by international registries. 
Each participating ICU included consecutive patients. To 
limit workload during the pandemic, centres were not 
asked to protocol a screening log. A diagnosis of COVID-
19 was made based on a positive polymerase chain reac-
tion (PCR) test.
Study population
Eligible patients were 70  years or older with a proven 
diagnosis of COVID-19 and admitted to an intensive care 
unit (ICU). Pre-ICU triage was not part of this study. To 
avoid duplication caused by the transfer of a patient from 
one ICU to another, each patient could only be entered 
once into the database regardless of readmission, transfer 
or other reason. This resulted in a unique electronic data-
base record for each patient. The reference date was day 
1 of the first admission to an ICU. All consecutive days 
were numbered sequentially from the day of admission. 
To limit bias in the comparison of the two surges, only 
patients admitted to an ICU in a European country that 
recruited patients during both surges were included in 
the analysis (Additional file 5).
Data collection
Centres collected data using the online case record 
form (CRF). Day one sequential organ-failure assess-
ment (SOFA) score on admission was calculated either 
manually or using an online calculator in the electronic 
CRF as described previously [11, 12]. The  PaO2/FiO2 
ratio  (PaO2/FiO2-index) on admission was calculated 
using the arterial  PO2 [mmHg] and the  FiO2 [fraction 
of 1] from the first arterial blood gas. ICU length of stay 
(LOS) was recorded in hours. As described previously, 
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[11] the electronic CRF and database ran on a secure 
server set up by and stored at Aarhus University, 
Aarhus, Denmark.
Frailty, comorbidities and organ support
The frailty level prior to the acute illness and hospital 
admission was assessed using the Clinical Frailty Scale 
(CFS) as published previously [12]. A detailed defini-
tion of co-morbidities and organ support can be found 
in Additional file 6. In addition, the place of living (hab-
itat) was collected using the following categories: own 
household, household with family or caregivers, nurs-
ing home, in-patient in hospital.
Outcome measurement
Patients were followed up until 90  days or death. The 
primary endpoint was survival at 30  days, the second-
ary endpoint survival at 90 days. Data could be retrieved 
either directly, from the hospital administration system 
or after discharge using telephone follow-up. Limitation 
of life-sustaining therapies such as withholding or with-
drawing organ support was documented [13].
Statistical analysis
Baseline characteristics of patients were analysed as 
frequencies and percentages for categorical variables 
and as medians and interquartile ranges (IQRs) for 
continuous variables. Comparisons between the two 
periods were evaluated using the Kruskal–Wallis test 
(ANOVA) for continuous variables and the χ2 or Fisher 
exact test for categorical variables as appropriate. Com-
parisons between surges were evaluated using the Wil-
coxon test for continuous variables and the χ2 or Fisher 
exact test for categorical variables as appropriate.
Incidence of organ support and treatment limitations 
were estimated using cumulative incidence analysis 
considering ICU death and ICU discharge as competing 
risks. Univariate comparisons were performed using 
Gray’s test.
The crude overall survival up to 90  days after ICU 
admission was estimated by the Kaplan–Meier method 
and compared between groups using a log-rank test.
In order to compare survival between the two surges 
adjusting for patients characteristics, a Cox model was 
fitted including the following variables: age, sex, PaO2/
FiO2 ratio, other SOFA components, frailty, BMI, habitat 
and comorbidities (definition in Additional file 6). Robust 
sandwich estimators to estimate the variance–covariance 
matrix of the regression coefficient estimates were used 
to account for clustering of patients within centres.
For continuous covariates, the martingale residu-
als was plotted against the covariates to assess the 
functional form of a covariate and eventually to detect 
nonlinearity.
In order to test proportional assumption, for each 
covariate independence between scaled Schoenfeld resid-
uals was tested, a global test was also performed for the 
model as a whole [14].
As survival difference between surges was not constant 
over time and in order to investigate whether the survival 
difference was due to a change of strategies in ICU or 
hospitals, survival before and after day 15 (median ICU 
stay for patients discharged alive during the first surge) 
was studied separately. This was done in order to identify 
factors relevant for outcome earlier and later during the 
treatment course.
We first estimated our models on the complete data set 
and then used multiple imputation for participants with 
missing data, using predictive mean matching for con-
tinuous variables, logistic regression for binary data, and 
polytomous regression for (unordered) categorical data. 
The cumulative baseline hazard was approximated by 
the Nelson–Aalen estimator and included in the imputa-
tion model [15]. Hundred imputations were drawn. Cox 
models were estimated in each imputed datasets, and 
estimates were combined using Rubin’s rules to give an 
overall estimate of parameters and corresponding vari-
ance–covariance matrix. Robust sandwich estimators to 
estimate the variance–covariance matrix of the regres-
sion coefficient estimates were used to account for clus-
tering of patients within centres.
Incidence of organ support and treatment limitations 
were estimated using cumulative incidence analysis 
considering ICU death and ICU discharge as compet-
ing risks. Univariate comparisons were performed using 
Gray’s test.
The general statistical analysis was conceptualised dur-
ing the set-up of the study at the beginning of the pan-
demic but has been revised during the analysis of the 
data obtained.
All p values were two-sided, and p < 0.05 was consid-
ered statistically significant. Statistical analyses were per-
formed with R 3.2.3 software packages (R Development 
Core Team, Vienna, Austria).
Results
As illustrated in Table  1, 2625 patients from European 
countries were included in the COVIP study during the 
two surges. There were nearly equal numbers of patients 
recruited during the first and the second surge of the 
pandemic. In the first surge, 4/1327 patients were lost to 
follow-up and in the second surge, 25/1298 patients were 
lost to follow-up. During these two surges, patient char-
acteristics changed, with slightly increasing age, body 
mass index, and CFS. In addition,  PaO2/FiO2 ratio and 
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SOFA score were lower in patients during the second 
surge of the pandemic and there was an increased preva-
lence of diabetes mellitus and ischemic heart disease.
During the second surge of the pandemic, manage-
ment had changed when compared with the first surge 
of the pandemic (Table  2). Patients were intubated for 
mechanical ventilation less frequently and if mechanical 
ventilation was performed, intubation took place later. By 
contrast, non-invasive ventilation was performed more 
often. Prone positioning was equivalent during both peri-
ods. Renal replacement therapy and treatment with vaso-
active substances were performed less frequently in the 
second surge. This is also illustrated by the time-to-event 
analysis as outlined in Fig.  1. Treatment with antibiot-
ics decreased, while the treatment with corticosteroids 
increased. Of note, there was no difference in withhold-
ing or withdrawal of treatment.
We observed a lower rate of survival in the second surge 
of the pandemic (Table 3, Fig. 2, log rank: p < 0.001). Sur-
vival before 15 days was found to be similar for patients 
during the two surges; the unadjusted hazard ratio (HR) 
for survival before 15  days for the second versus first 
surge was 1.06 (95% CI 0.85–1.32, p = 0.62). Survival 
after day 15 was found to be worse for patients admitted 
to ICU during the second surge than for patients admit-
ted during the first surge (Fig.  3). The unadjusted HR 
for survival after day 15 for the second surge versus first 
surge was 1.73 (95% CI 1.35–2.22, p < 0.001).
This survival difference persisted after adjustment for 
age, sex,  PaO2/FiO2 ratio, other SOFA component, CFS, 
BMI, habitat and comorbidities (Table  4, HR > 1 repre-
sents increased mortality). Of note, important differences 
between the first and the second surge associated with 
worse outcome after day 15 are sex and kidney failure 
(Table 4B). All statistical details on this analysis with and 
without imputation for missing data for the overall sur-
vival probability analysis until day 90 are given in Addi-
tional file 7.
Also, the overall survival probability analysis con-
firmed increased mortality in the second surge. Fur-
thermore, decreased survival has been confirmed 
by several sensitivity analyses for survival analysis 
Table 1 Baseline characteristics of the study population across the two surges
First surge (until 26 
May 2020)












Age (years) 74 (72–78) 4 75 (72–79) 1 0.02
Sex (male sex) 74% 4 70% 1 0.04
Weight (kg) 80 (72–90) 107 80 (72–91) 45 0.30
Height (cm) 170 (165–177) 142 170 (164–177) 67 0.12
BMI (kg/m2) 27.5 (24.7–30.1) 154 27.6 (24.9–31.1) 77 0.03
Clinical status
CFS 3 (2–4) 114 3 (2–4) 116 0.0011
SOFA 6 (3–8) 13 5 (3–7) 28  < 0.0001
PaO2/FiO2 ratio 126 (84–181) 18 104 (75–156) 63  < 0.0001
Comorbidities
Diabetes mellitus (%) 31% 8 36% 10 0.0097
Ischemic heart disease (%) 20% 22 25% 17 0.0004
Chronic kidney disease (%) 15% 14 17% 14 0.22
Arterial hypertension (%) 66% 9 67% 8 0.52
Chronic pulmonary disease (%) 22% 16 23% 9 0.45
Chronic heart failure (%) 14% 22 15% 17 0.72
Habitat categories
Own home 78% 0 80% 0 0.0001
Other home with family or caregivers 6% 0 6% 0
Nursing home 4% 0 2% 0
Hospital ward 6% 0 8% 0
Other/Unknown 6% 0 4% 0
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(Additional file  8) and the adjusted survival mod-
els (model 2, HR > 1 indicates increased mortality in 
the second surge): patients’ age > 75: HR 1.35 (95% CI 
1.12–1.62); patients with diabetes mellitus: HR 1.32 
(95% CI 1.06–1.64); patients receiving mechanical 
ventilation: HR 1.45 (95% CI 1.21–1.73). Four coun-
tries were found to have recruited with asymmet-
ric geometry across supplemental surges. However, 
a sensitivity analysis excluding these four countries 
confirmed previous findings (Additional file  9). In 
addition, Additional file 9 gives the sensitivity analysis 
excluding the first four weeks of each surge confirm-
ing previous findings.
Discussion
In this study of patients aged 70 and above admitted 
with COVID-19 disease, we found a decrease in thirty-
day survival from 57% in the first surge to 49% in the 
second surge, even after adjustment for important co-
factors such as age, gender, SOFA score, comorbidities 
and frailty. The major differences between the two groups 
besides mortality were the reduction in the use of intuba-
tion and mechanical ventilation and its early use, reduced 
use of vasoactive drugs, increased use of non-invasive 
ventilation (NIV) and an increased use of corticoster-
oids during the second surge. Although management of 
patients changed, we cannot clearly attribute the change 
in outcome to a specific change in practice.
These findings are surprising, as the ICU community 
had gained experience in treating these patients during 
the first surge. Here, the initial very high reported [16] 
mortality was soon followed with a reduction in mortal-
ity towards the end of the first surge [17]. It was thought 
that in the second surge, the use of steroids in patients 
with severe respiratory distress, and the delay in intuba-
tion, following the use of NIV to its full potential would 
translate to better outcomes. However, our detailed 
analysis revealed that besides the treatment during 
the second surge, older age, male sex, increased frailty, 
increased SOFA score and chronic kidney disease were 
Table 2 Management of patients during the first and second surge of the pandemic
First surge (until 26 May 
2020)
Second surge
1 September–31 December 
2020
p value
Patients (n) 1327 1298
Time periods
Days with symptoms prior to hospital admission 7 (4–10) 7 (4–10) 0.35
Days in the hospital prior to ICU admission 2 (1–4) 2 (1–5) < 0.0001
Length of ICU stay for patients discharged alive (days) 15 (6–29) 10 (5–20) < 0.0001
Respiratory management
Mechanical ventilation started on day 1 58% 42% < 0.0001
Mechanical ventilation
Cumulative incidence at day 15







Cumulative incidence at day 15






Non-invasive or mechanical ventilation
Cumulative incidence at day 15







Cumulative incidence at day 15







Vasoactive drugs 77% 67%  < 0.0001
Renal replacement therapy 18% 14% 0.0069
Corticosteroids 38% 93%  < 0.0001
Antibiotics 92% 88% 0.0009
Withholding or Withdrawal of treatment modalities
Cumulative incidence at day 15
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associated with poor outcome especially 15  days after 
ICU admission.
To date, there are only very few reports comparing 
the two surges in COVID-19 hospitalised patients. In 
a study from 955 US hospitals, researchers compared a 
trend analysis for the first surge: from 1 January to 30 
April 2020 and 1 May to 30 June 2020. The overall hos-
pital event rate for 30 day mortality or referral to hos-
pice within 30 days fell from 16.56 to 9.29%, indicating 
improved outcome in the last period of the first surge 
suggesting a steep learning curve [18]. This has also 
been confirmed by a study from the UK in > 21,000 crit-
ical care patients with COVID-19 showing improved 
survival from March to June 2020 [19]. In another study 
looking at COVID-19 outcomes in hospitalised patients 
with rheumatic disease, outcomes from the first 90 days 
were compared to the following 90  days [20]. They 
found a reduced risk of hospitalisation and admission 
to an ICU in the late cohort, and also a fall in the risk of 
death (9.3% versus 4.5%).
Fig. 1 Cumulative incidences for a mechanical ventilation (MV), b non-invasive ventilation (NIV), c combined MV and NIV, d vasoactive drugs, e 
renal replacement therapy (RRT), and f treatment limitation during the first and the second surge
Table 3 Survival estimates after ICU admission during the two 
surges
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Our patients were all treated in the ICU during both 
surges, and therefore, a comparison with these ini-
tial experiences from other patient groups is difficult. 
However, reports from Intensive Care National Audit 
and Research Centre (ICNARC) in the UK reveal valu-
able information in this respect. This national registry 
Fig. 2 Kaplan–Meier curve until 90 days for patients admitted during the first and the second surge
Fig. 3 Overall survival probability plots a the entire cohort until day 90 following ICU admission; b a comparison between the two surges until day 
15 after ICU admission; c landmark analysis comparing the two surges for patients alive at day 15 after ICU admission
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Table 4 Detailed analysis of factors associated with outcome in the treatment periods before and after 15 days after ICU admission. 
This landmark analysis allows differentiation of factors that are relevant for outcome earlier and later during the disease course
HR (95% CI) p value
(A) Analysis of overall survival probability before day 15 (N = 2625 patients)
Surge Second versus first 1.04 (95% CI 0.83–1.3) 0.7293
Frailty (ref = Fit) Vulnerable (CFS 4) 1.27 (95% CI 0.97–1.68) 0.0863
Frail (CFS 5–8) 2.03 (95% CI 1.6–2.58)  < 0.0001
Age One year increase 1.07 (95% CI 1.05–1.09)  < 0.0001
Habitat (ref = own home) Other home with family or caregivers 1.36 (95% CI 1–1.84) 0.0506
Nursing home 0.68 (95% CI 0.36–1.28) 0.2343
Hospital ward 0.94 (95% CI 0.57–1.53) 0.7914
Other/unknown 0.71 (95% CI 0.44–1.15) 0.1635
Sex Female versus male 0.96 (95% CI 0.8–1.14) 0.6154
PaO2/FiO2 ratio One point increase 1 (95% CI 1–1) 0.1628
Sofa_neuro One point increase 1.15 (95% CI 1.06–1.25) 0.0009
Sofa_cardio One point increase 1.01 (95% CI 0.95–1.07) 0.6976
Sofa_liver One point increase 1.09 (95% CI 0.92–1.31) 0.3166
Sofa_coag One point increase 1.17 (95% CI 1–1.37) 0.0499
Sofa_kidney One point increase 1.31 (95% CI 1.19–1.43)  < 0.0001
BMI One point increase 1.01 (95% CI 0.99–1.03) 0.2848
Diabetes (any type) Yes versus no 1.13 (95% CI 0.93–1.39) 0.2196
Ischemic heart disease Yes versus no 1.14 (95% CI 0.91–1.42) 0.2495
Renal insufficiency Yes versus no 0.95 (95% CI 0.73–1.23) 0.6927
Arterial hypertension Yes versus no 0.88 (95% CI 0.75–1.02) 0.0954
Pulmonary comorbidity Yes versus no 1.07 (95% CI 0.9–1.28) 0.4122
Chronic heart failure Yes versus no 1.1 (95% CI 0.84–1.43) 0.5031
(B) Landmark analysis of overall survival probability after day 15 (patients alive 15 days after ICU admission and with follow-up > 15 days—N = 1790)
Surge Second versus first 1.87 (95% CI 1.44–2.43)  < 0.0001
Frailty (ref = Fit) Vulnerable (CFS 4) 1.24 (95% CI 0.91–1.69) 0.1661
Frail (CFS 5–8) 1.53 (95% CI 1.11–2.11) 0.0088
Age one year increase 1.04 (95% CI 1.02–1.06) 0.0008
Habitat (ref = own home) Other home with family or caregivers 1.23 (95% CI 0.83–1.83) 0.3048
Nursing home 0.43 (95% CI 0.17–1.09) 0.0738
Hospital ward 0.98 (95% CI 0.7–1.37) 0.9088
Other/unknown 0.86 (95% CI 0.55–1.32) 0.4847
Sex Female versus male 0.75 (95% CI 0.6–0.93) 0.0088
PaO2/FiO2 ratio One point increase 1 (95% CI 1–1) 0.3833
Sofa_neuro One point increase 1.2 (95% CI 1.08–1.34) 0.0007
Sofa_cardio One point increase 1.06 (95% CI 1–1.13) 0.0562
Sofa_liver One point increase 0.94 (95% CI 0.77–1.14) 0.5151
Sofa_coag One point increase 1.14 (95% CI 0.96–1.34) 0.1257
Sofa_kidney One point increase 1.1 (95% CI 0.98–1.23) 0.1251
BMI One point increase 0.99 (95% CI 0.97–1.02) 0.5460
Diabetes (any type) Yes versus no 1.09 (95% CI 0.9–1.33) 0.3719
Ischemic heart disease Yes versus no 0.77 (95% CI 0.57–1.05) 0.0956
Renal insufficiency Yes versus no 1.39 (95% CI 1.02–1.9) 0.0366
Arterial hypertension Yes versus no 0.92 (95% CI 0.77–1.09) 0.3095
Pulmonary comorbidity Yes versus no 1.07 (95% CI 0.89–1.28) 0.4579
Chronic heart failure Yes versus no 0.87 (95% CI 0.65–1.18) 0.3786
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compared patients admitted before and after 1 Sep-
tember, 2020, and found a small increase in mortality 
in patients ventilated within the first 24  h from 46.6% 
in the first to 48.7% in the second cohort and a simi-
lar reduction in all patients discharged alive from the 
ICU [21]. Their results were also similar to our patient 
cohort in other respects, with considerably fewer 
patients receiving mechanical ventilation, (down from 
72 to 50%) and more patients given basic respiratory 
support (from 25 to 47%). In addition, the duration of 
mechanical ventilation was shorter. Analogous to our 
results, they found that more patients had a low  PaO2/
FiO2 ratio at admission.
There are several possible reasons for the increased 
mortality seen in our study although we can only describe 
associations in this kind of study setting. While our data 
do not give a satisfactory explanation, it allows for sev-
eral potential contributing factors to be discussed and 
to guide specific attention to differences occurring dur-
ing the disease course, such as the increasing relevance of 
kidney failure and potential gender differences after day 
15.
A worse outcome might have been caused by the 
increased length of time spent in other departments 
before ICU admission, resulting in patients deteriorat-
ing prior to eventual admission. This is supported by 
a decreased  PaO2/FiO2 ratio seen at ICU admission in 
the second period, possibly suggesting more severe res-
piratory failure. This combined with a trend towards a 
reduction in the use of mechanical ventilation may not 
have been beneficial in this group of elderly critically ill 
patients, although this remains speculative. Although 
several studies and a meta-analysis suggested that timing 
of intubation may have no effect on mortality and mor-
bidity in COVID-19 [22], this remains to be confirmed 
in elderly patients. Also failure of non-invasive ventila-
tion with delayed intubation needs to better defined, with 
especially high mortality rates [23].
A similar rate of limitation of life-sustaining therapy 
was seen in the two cohorts, so this is unlikely to account 
for the difference in mortality. Two additional differences 
are a slight increase in age and frailty score in the second 
cohort, which could explain an increase in mortality; 
however, the difference in mortality remained even after 
adjustment for these factors.
Another possible explanation for the increased mor-
tality, which cannot be ruled out, could be a reduc-
tion in quality of care, despite all dedicated efforts on 
the part of the staff, in the second compared to the 
first surge. When the second surge started, many hos-
pitals and in particular ICUs had already been over-
stretched for half a year and were running well above 
their usual capacity. This had consequences for both 
the permanent staff who had been working increased 
hours over a long period of time, and also the continu-
ous dilution of expertise as non-ICU personnel, both 
physicians and nurses were being brought in to work in 
ICUs. There has been great concern about the burden 
of work on the health of ICU workers [24], leading to 
fatigue and physical and mental health problems, which 
ultimately may affect quality of care. In the current sur-
vival analysis, survival differs from day 15 onwards and 
it is tempting to speculate that quality of care in par-
ticular had consequences for elderly patients with pro-
longed treatment duration.
Another important factor may be related to use of 
corticosteroids. In the second surge, 93% of our patients 
received corticosteroids, which is more than twice that 
found in the first cohort. It is well documented that 
steroids have potentially serious side effects in ICU 
patients. Steroids increase infection rate and hence 
mortality in patients admitted with influenza pneu-
monia [25] and thus could also increase the number 
of patients acquiring sepsis in the ICU. It was of inter-
est to study the details in the supplementary appendix 
from the RECOVERY study where COVID-19 patients 
were randomised to receive corticosteroids [7]. Only a 
small number of patients requiring mechanical venti-
lation were over 70 years old. In a pre-specified analy-
sis of the RECOVERY trial, there was no difference in 
mortality in patients above 70  years. Despite this, that 
landmark trial—among others—changed guidelines 
[26] and practice independent of age, in severely ill 
COVID-19 patients. Although the RECOVERY trial is a 
major achievement in these difficult times, some unan-
swered questions remained. For example, it was unclear 
whether patients with uncontrolled diabetes, acute 
delirium, underlying malignancy, immunosuppression, 
or other conditions in which corticosteroids might have 
harmful effects were included [8, 27].
Finally, development of COVID-19 mutations may 
change virulence and hence potentially lead to worse out-
comes. It is well known that during the pandemic a new 
mutant virus emerged in Europe [28]. The clinical prop-
erties of this new strain are largely unknown as whole 
genome sequence studies have not been performed in 
large scale and ordinary COVID-19 testing does not dif-
ferentiate mutant viruses from the original one. Such a 
cause for worse outcomes is uncertain but remains a the-
oretical possibility.
Another possible explanation could be selection bias 
creating differences between the cohort in the first and 
second surge. That patients are already selected before 
ICU admission is common, and many undergo formal 
and informal triage. Criteria for triage were extensively 
discussed from the beginning of the pandemic when 
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some ICUs experienced a rapid overflow of patients. We 
do not have detailed insight in what happened before 
ICU admission in our study, as this was not a research 
question. There are, however, some casemix differences 
between the first and second surge, mainly connected 
to longer time in hospital before ICU admission dur-
ing the second surge, and a decreased oxygen ratio at 
ICU admission. This indicates potential differences in 
initial treatment leading to changes in selection maybe 
connected with increased knowledge of the feasibility 
to treat some severe covid-19 patients outside the ICU 
[29].
Our study has further weaknesses mainly concerning 
the absence of details of variables that might account for 
our differences in outcome. There was no information 
about how steroids were administered, no control group 
of younger COVID-19 patients for comparison and 
there was no information about quality of care and the 
nurse-to-patient ratios as well as a measure of stress for 
personnel. Also, admission policies or local guideline 
changes were not recorded. The recording of treatment 
limitations is not without difficulties but important in 
ICU studies in elderly patients [30]. The reception of 
this might differ across study sites reflecting a wide het-
erogenicity. In addition, although we provided defini-
tion of the comorbidities, their characterisation do not 
provide in-detail characterisation and differ across stud-
ies in the literature. Also, data on anticoagulation, seda-
tion practices and on lung-protective ventilation were 
not collected which might account for outcome differ-
ences. Another limitation is that we did not ask centres 
to monitor consecutive inclusion with a screening log, 
serving as proofs of consecutive recruitment and allow-
ing generalizability. We have no proofs that all eligi-
ble patients in all centres have been included into the 
study. Our observations can only describe associations 
without ascribing causality; however, we have observed 
that an untargeted but consistent change in practice has 
changed the outcomes between the cohorts in the two 
surges.
Conclusion
This is the first study in critically ill elderly ICU patients 
with COVID-19 infection that compares mortality 
data between the first and second surges of the pan-
demic. We have found an unexpected but significant 
rise in mortality in elderly COVID-19 patients treated 
in the ICU during the second surge. The cause of this 
rise is unknown but possible explanations have been 
discussed. Our main concern is whether the wide-
spread changes in practice and treatment of COVID-
19 between the two surges have contributed to this 
increased mortality in elderly patients. Further studies 
are urgently warranted to provide more evidence for 
current practice in elderly patients.
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